Guardant Health, Inc. (NASDAQ:GH – Get Free Report) CEO Amirali Talasaz sold 37,500 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $169.16, for a total value of $6,343,500.00. Following the completion of the sale, the chief executive officer directly owned 37,500 shares of the company’s stock, valued at $6,343,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Amirali Talasaz also recently made the following trade(s):
- On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The stock was sold at an average price of $150.79, for a total transaction of $17,638,207.88.
- On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The shares were sold at an average price of $151.54, for a total transaction of $21,674,463.12.
Guardant Health Price Performance
NASDAQ GH opened at $170.92 on Thursday. The company’s fifty day moving average is $156.17 and its two-hundred day moving average is $120.00. Guardant Health, Inc. has a 52-week low of $53.40 and a 52-week high of $176.58. The firm has a market capitalization of $22.94 billion, a price-to-earnings ratio of -48.97 and a beta of 1.60.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the stock. BTIG Research increased their price target on shares of Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wolfe Research assumed coverage on Guardant Health in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price objective on the stock. Bank of America increased their target price on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research note on Tuesday. Finally, Canaccord Genuity Group increased their target price on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and a consensus price target of $183.78.
Get Our Latest Stock Analysis on Guardant Health
Institutional Investors Weigh In On Guardant Health
A number of institutional investors and hedge funds have recently made changes to their positions in GH. Orbimed Advisors LLC bought a new position in shares of Guardant Health in the 1st quarter worth $40,199,000. World Investment Advisors bought a new stake in shares of Guardant Health during the fourth quarter worth about $1,664,000. Ninepoint Partners LP acquired a new stake in shares of Guardant Health in the 2nd quarter worth about $2,853,000. GSA Capital Partners LLP acquired a new stake in shares of Guardant Health in the 2nd quarter worth about $1,772,000. Finally, SWS Partners bought a new position in Guardant Health in the 2nd quarter valued at about $11,190,000. Institutional investors own 92.60% of the company’s stock.
About Guardant Health
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
- Five stocks we like better than Guardant Health
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
